Germany· DE-A57-05a0fef02922ccbe
Edronax
A reboxetine product containing reboxetine, registered in Germany by Kohlpharma Gmbh. The same ATC class is registered in 8 of our 19 countries.
Checked against EMA Article 57 (European Union) on
Informational only — not a medical device.
Where it is registered
Reboxetine is registered in 8 of 19 countries.
Countries holding a registration under ATC N06AX18 (reboxetine), each read from that country’s own register.
- This record: Germany, from EMA Article 57 (European Union)
- 5 of them publish a price we can compare per daily dose
Reboxetine · ATC N06AX18
8 / 19 countries
- Belgiumprice
- Finlandprice
- Germany
- Ireland
- Italyprice
- Polandprice
- Switzerlandprice
- United Kingdom
Price per daily dose
What a daily dose of reboxetine costs, country by country.
Normalised to the WHO defined daily dose (8 mg), the median price runs from $1.04 in Italy to $2.27 in Switzerland — a ×2.2 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Reboxetine · price per daily dose (8 mg)
USD · FX 28 Sept 2026
- CH Switzerland$2.27
- IT Italy$1.04
The record
At a glance
EMA Article 57 (European Union)- Active substance
- Reboxetine
- Manufacturer
- Kohlpharma Gmbh
- Country
- Germany (DE)
- ATC code
- N06AX18
- ATC class
- Reboxetine
- Defined daily dose
- 8 mg, O
- Reimbursed
- Not published by this register
- Source register
- EMA Article 57 (European Union)
- Last checked
- September 30, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
19 interactions on record for reboxetine.
Mechanism, severity and management for each pair, from a commercially licensed source — included with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Reboxetine · interactions on record
19 records
19 more interactions with mechanism and management, from a commercially licensed source.
Sign in to checkSame class
Other records under N06AX18
Reboxetine, as other registers publish it.
- FinlandEdronaxPfizer Oy
- FinlandEdronaxPfizer Oy
- PolandEdronaxPfizer Europe MA EEIG
- BelgiumEdronax 4 mgPfizer
- United KingdomEdronax 4mg tabletsWaymade Healthcare Plc
- United KingdomEdronax 4mg tabletsCST Pharma Ltd
- United KingdomEdronax 4mg tabletsSigma Pharmaceuticals Plc
- United KingdomEdronax 4mg tabletsDowelhurst Ltd
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of EMA Article 57 (European Union). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/8392a4e8-a8a0-4318-80b8-c63880945ed4 GET /v1/drugs/8392a4e8-a8a0-4318-80b8-c63880945ed4?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"pzn": null,
"route": "Oral Use",
"source": "ema_art57_de",
"ma_number": null,
"substance": "Reboxetine",
"atc_from_source": null,
"authorisation_country": "Germany"
}See everything about reboxetine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.